News

The U.S. Food and Drug Administration (FDA) has named  Cala Trio a breakthrough device as a potential wrist-worn treatment of action tremors in the hands of adults with Parkinson’s disease. This designation is given to medical devices with the potential to more effectively treat diseases that are life-threatening or irreversibly debilitating. It…

Sanofi will provide $1 million in research funding over the next two years to support PD GENEration, a national initiative seeking to increase the availability of genetic testing and counseling for people with Parkinson’s disease living in the U.S. “Genetic testing is critical for advancing…

Roche, in partnership with Prothena, will launch a Phase 2b clinical trial to evaluate the effectiveness of prasinezumab (PRX002/RG7935) — an antibody against the alpha-synuclein protein — in people with early stage Parkinson’s disease, including those on stable levodopa treatment. The decision was based on positive data from a…

In patients with Parkinson’s disease, dopamine-producing neurons and microglia cells — the “immune cells” of the brain — accumulate fatty molecules that may promote inflammation and disease progression, a new study has found. The findings, according to researchers, suggest that therapies capable of restoring the balance of…

Scientists found a species of bacteria living in the small intestine, called Clostridium sporogenes, that is able to convert a fraction of unabsorbed levodopa — a medication commonly used to treat Parkinson’s disease — into a chemical that lowers gastrointestinal mobility. According to authors, this process may…

The association between dopamine levels and electric brain signals called beta waves — thought to be of an opposite nature based on data from people with Parkinson’s disease — is more complex than previously thought, a study in non-human primates shows. The data, collected through a new chemo-electric platform,…

People with early-onset Parkinson’s disease caused by mutations in the PRKN or PINK1 genes have high levels of the pro-inflammatory immune signaling protein interleukin-6 and mitochondrial DNA in the blood, which may…

Buspirone can effectively ease anxiety among people with Parkinson’s disease, but the medication is not well tolerated, according to data from a recent Phase 2 trial. Patients using this anti-anxiety medication and able to tolerate it well should continue its use, but a large-scale study is not advised, its…

Pharmather has entered into an exclusive licensing agreement with the University of Arizona, allowing the company to further develop ketamine as a potential treatment of dyskinesia — involuntary, jerky movements — associated with levodopa use in people with Parkinson’s disease. The company plans…

Anavex 2-73 (blarcamesine), a potential oral therapy to slow cognitive decline due to Alzheimer’s and other neurological disorders, was found to be safe and to lead to clinically meaningful, dose-dependent improvements in cognition in people with Parkinson’s disease dementia (PDD) treated in a Phase 2 trial. Anavex…